Ovarian cancer: epigenetics, drug resistance, and progression

Table 2 Application of miRNA to OC drug resistance

miRNA	Resistance against	Function	Target/Pathway	References
miR-708	Cisplatin	Inhibition of metastasis	IGF2BP1/Akt	[49]
miR-136	Paclitaxel	Inhibition of proliferation	Notch3	[51]
miR-744-5p	Carboplatin	Promotion of cell apoptosis	NFIX and HNRNPC	[138]
miR-98-5p	cisplatin	Promotion of drug resistance	miR-98-5p/Dicer1/miR-152	[58]
miR-1246	Paclitaxel	Promotion of tumor growth	Cav1/p-gp/M2-type macrophage axis	[53]
miR-142-5p	Cisplatin	Inhibition of drug resistance	XIAP, BIRC3, BCL2, BCL2L2, and MCL1(?)	[139]
miR-509-3p	Platinum	Enhance drug sensitivity	GOLPH3 and WLS	[140]
miR-34a	Cisplatin	Inhibition of proliferation	HDAC1	[50]
miR-338-3p	Cisplatin	Inhibition of proliferation, motility, and EMT	WNT2B	[141]
miR-1307	Paclitaxel	Affects cell cycle dynamics	CIC	[142]
miR-383-5p	Paclitaxel	Tumor suppressor	TRIM27	[52]
miR-206		Inhibition of proliferation and metastasis	c-Met/AKT/mTOR Signaling Pathway	[143]
miR-503-5p	Paclitaxel	Inhibition of tumor angiogenesis and growth	CD97-Mediated JAK2/STAT3 Pathway	[54]
miR-30a-5p		Inhibition of migration and invasion	SKP2, BCL9, and NOTCH1	[144]
miR-34a-5p	Cisplatin	Inhibition of proliferation and G1-phase cell cycle	PD-L1	[145]

ISSN: 1475-2867